Filing Flows › Retractable Technologies (RVP) › Q1 2026 › vs Q1 2025
Retractable Technologies (RVP) Q1 2026 vs Q1 2025 (year over year)
Retractable Technologies's revenue fell $1.1M (-13%) from $8.3M in Q1 2025 to $7.2M in Q1 2026. The biggest changes: Syringes −$1.2M (-17%); Blood Collection Products +$31K (+9%); EasyPoint Needles +$10K (+1%).
Retractable Technologies, Q1 2026: revenue $7.2M (-14% year over year), operating margin -85.9%, net loss $4.2M, operating cash flow −$1.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Syringes | $5.8M | $7.0M | −$1.2M | -17% |
| EasyPoint Needles | $993K | $984K | $10K | +1% |
| Blood Collection Products | $375K | $344K | $31K | +9% |
| Other Products | $7K | $8K | −$1K | -9% |
| Revenue | $7.2M | $8.3M | −$1.1M | -13% |
| Other income, net | $1.9M | −$5.5M | $7.5M | — |
| Net loss | $4.2M | $10.5M | −$6.3M | -60% |
| Costs & expenses | $13.3M | $18.8M | −$5.4M | -29% |
| Operating costs | $13.3M | $13.0M | $373K | +3% |
| Income tax | $2K | $286K | −$284K | -99% |
| Cost of revenue | $8.0M | $8.3M | −$281K | -3% |
| Research & development | $170K | $191K | −$21K | -11% |
| Sales & marketing | $1.7M | $1.6M | $132K | +8% |
| General & admin | $3.4M | $2.9M | $543K | +19% |
| Operating cash sources | $4.2M | $10.5M | −$6.3M | -60% |
| Depreciation & amortization | $1.9M | $1.9M | $22K | +1% |
| Working capital & other | $952K | $7.1M | −$6.2M | -87% |
| Cash used in operations | $1.4M | $1.5M | −$107K | -7% |
| Net loss absorbed | $4.2M | $10.5M | −$6.3M | -60% |
Questions
How much did Retractable Technologies's revenue grow year over year in Q1 2026?
Retractable Technologies's revenue fell $1.1M (-13%) from $8.3M in Q1 2025 to $7.2M in Q1 2026.
What drove Retractable Technologies's revenue change in Q1 2026?
Syringes −$1.2M (-17%); Blood Collection Products +$31K (+9%); EasyPoint Needles +$10K (+1%).